Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases. Co.'s pipeline is focused in three main areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. Co. is developing CAR T therapies for hematologic malignancies in partnership with City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Co. is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105). The MBIO average annual return since 2017 is shown above.
The Average Annual Return on the MBIO average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MBIO average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|